Evoq Remedies Ltd
Evoq Remedies Ltd (EVOQ) last reported results for the quarter ended Mar 2026, with sales of ₹0 crore and net profit of ₹-0.29 crore. Evoq Remedies Ltd’s annual general meeting is scheduled for 30 Oct 2026. The stock last traded at ₹1.46, a market capitalisation of ₹3.64 crore. Over the past 52 weeks the stock has ranged between ₹1.35 and ₹6.11. Figures are as of 6 Oct 2026 and are not real time.
Evoq Remedies Ltd share price and key metrics
- Current price
- ₹1.46
- Market cap
- ₹3.64 cr
- Book value
- ₹17.8
- ROE
- -0.54%
- ROCE
- -0.56%
- Dividend yield
- 0.00%
- 52w high / low
- 6.11/1.35
Metrics as of 6 Oct 2026. Not real time.
Track Evoq Remedies Ltd
Cruxal reads every Evoq Remedies Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Evoq Remedies Ltd growth and returns
- 10 Years
- %
- 5 Years
- 21%
- 3 Years
- 8%
- TTM
- 117%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -367%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -52%
- 1 Year
- -62%
- 10 Years
- %
- 5 Years
- 2%
- 3 Years
- 0%
- Last Year
- -1%
Evoq Remedies Ltd quarterly results
In the quarter ended Mar 2026, sales were ₹0 cr, down 100.0% from ₹11.76 cr a year earlier. Net profit swung to a loss of ₹0.29 cr.
| ₹ crore | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 15.79 | 4.6 | 3.9 | 0.15 | 0 | 11.76 | 25.51 | 0 |
| Expenses | 15.48 | 8.64 | 3.83 | 1.87 | 1.63 | 12.36 | 26.46 | 0.5 |
| Operating profit | 0.31 | -4.04 | 0.07 | -1.72 | -1.63 | -0.6 | -0.95 | -0.5 |
| OPM % | 1.96% | -87.83% | 1.79% | -1,146.67% | — | -5.10% | -3.72% | — |
| Other income | 0 | 6.02 | 0 | 2.26 | 0.01 | 2.4 | 1.06 | 0.19 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0.04 | 0.03 | 0.02 |
| Profit before tax | 0.31 | 1.98 | 0.07 | 0.54 | -1.62 | 1.76 | 0.08 | -0.33 |
| Tax % | 0.00% | 33.84% | 28.57% | 29.63% | 0.00% | 2.27% | 25.00% | -12.12% |
| Net profit | 0.31 | 1.31 | 0.05 | 0.38 | -1.62 | 1.71 | 0.05 | -0.29 |
| EPS (₹) | 0.23 | 0.96 | 0.04 | 0.28 | -0.65 | 0.69 | 0.02 | -0.12 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Evoq Remedies Ltd annual results
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3.25 | 9.07 | 10.02 | 16.78 | 20.39 | 4.05 | 11.76 | 25.51 |
| Operating profit | 0.02 | 0 | 0.95 | 1.46 | -3.73 | -1.64 | -2.23 | -1.45 |
| OPM % | 0.62% | 0.00% | 9.48% | 8.70% | -18.29% | -40.49% | -18.96% | -5.68% |
| Net profit | 0.01 | 0 | 0.72 | 1.09 | 1.62 | 0.45 | 0.09 | -0.24 |
| EPS (₹) | 10.00 | 0.00 | 720.00 | 0.80 | 1.19 | 0.33 | 0.04 | -0.10 |
TTM is the trailing twelve months to the most recent quarter.
Evoq Remedies Ltd balance sheet
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0.01 | 0.01 | 0.01 | 13.60 | 13.60 | 13.60 | 24.90 | 24.90 |
| Reserves | 0.01 | 0.01 | 0.73 | 9.57 | 11.19 | 11.64 | 19.64 | 19.40 |
| Borrowings | 0.00 | 0.01 | 0.00 | 8.16 | 9.58 | 4.24 | 0.00 | 0.07 |
| Other liabilities | 2.12 | 5.62 | 7.30 | 2.00 | 0.53 | 7.39 | 5.47 | 7.57 |
| Total liabilities | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 | 50.01 | 51.94 |
| Fixed assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.22 | 0.17 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other assets | 2.14 | 5.65 | 8.04 | 33.33 | 34.89 | 36.86 | 49.79 | 51.77 |
| Total assets | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 | 50.01 | 51.94 |
As reported by the company. Total assets equal total liabilities by construction.
Evoq Remedies Ltd cash flow
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0.01 | -0.02 | 0.03 | -26.43 | -4.35 | 5.32 | -14.62 | -0.28 |
| Cash from investing | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 | -0.26 | 0.00 |
| Cash from financing | 0.00 | 0.00 | 0.00 | 29.49 | 1.42 | -5.34 | 14.97 | 0.07 |
| Net cash flow | 0.01 | -0.02 | 0.03 | 3.06 | -2.94 | -0.03 | 0.09 | -0.21 |
| Free cash flow | 0.01 | -0.02 | 0.03 | -26.43 | -4.36 | 5.31 | -14.88 | -0.28 |
| CFO / operating profit | 50% | — | 3% | -1,785% | 99% | -334% | 654% | 19% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Evoq Remedies Ltd operating ratios
| Per year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 0.00% | 246.75% | 9.11% | 6.97% | 1.91% | 0.35% | -0.56% |
| Debtor days | 138.14 | 189.94 | 249.16 | 552.50 | 308.25 | 156.81 | 267.54 | 55.09 |
| Inventory days | 3.39 | 2.42 | 6.97 | 20.66 | 38.33 | 732.34 | 61.90 | 23.92 |
| Days payable | 239.57 | 226.66 | 315.25 | 32.05 | -10.20 | 767.44 | 97.59 | 10.89 |
| Cash conversion cycle | -98.04 | -34.30 | -59.11 | 541.11 | 356.78 | 121.72 | 231.85 | 68.12 |
| Working capital days | 1.12 | 1.21 | 26.23 | 436.56 | 440.90 | 2,263.00 | 1,369.06 | 631.27 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Evoq Remedies Ltd shareholding pattern
Promoters held 0.02% at Mar 2026, down from 11.21% at Jun 2024.
| % held | Mar 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 73.53% | 73.53% | 20.53% | 11.21% | 11.21% | 11.21% | 11.21% | 0.02% |
| Public | 26.47% | 26.47% | 79.47% | 88.79% | 88.79% | 88.78% | 88.79% | 99.98% |
| No. of shareholders | 707 | 727 | 1,672 | 1,588 | 1,577 | 1,723 | 1,679 | 1,655 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Evoq Remedies Ltd’s AGM?
Evoq Remedies Ltd’s annual general meeting is scheduled for 30 Oct 2026.
- AGMApproval of extension for AGM due to CIRP
See the full results calendar for every Indian company reporting in the next 30 days.
Evoq Remedies Ltd corporate filings
- Evoq Remedies Limited receives one-month extension to hold 16th AGM amid ongoing CIRP, with minimal financial activity reportedCompany Updatelow impact
Cruxal's analysis: Evoq Remedies Limited, a small-cap company with a market cap of approximately ₹3.79…
Read the full analysis - Intimation of Closure of Trading WindowInsider Trading / SASTlow impact
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.